

**Date: July 2, 2026**

<b>BSE Limited</b> <b>Listing Department-</b> <b>Phiroze Jeejeebhoy Towers</b> <b>Dalal Street</b> <b>Mumbai- 400001</b> <b>Scrip Code: 544292, ISIN: INE013P01021</b>	<b>National Stock Exchange of India Ltd</b> <b>Exchange Plaza, C-1, Block G,</b> <b>Bandra Kurla Complex,</b> <b>Bandra (E)</b> <b>Mumbai – 400 051</b> <b>Symbol: ONESOURCE</b>
---	---

Dear Sir/ Madam,

Subject: **Completion of US-FDA Inspection at Sterile Product Division facility at Bengaluru**

We wish to inform that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma Limited located at Opp. IIM, Bilekahalli, Bannerghatta Road, Bengaluru, 560076 from June 22, 2026 to June 30, 2026.

The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.

We will keep the stock exchanges informed of any further developments in this matter.

Please take the above information on record.

For and on behalf of  
**OneSource Specialty Pharma Limited**

**Trisha A**  
Company Secretary and Compliance Officer  
Membership Number: A47635